Theriva™ Biologics Reports Third Quarter 2026 Operational Highlights and Financial Results
Key Highlights
- ➤SYN-004 portfolio sold for $350,000 upfront, up to $91 million milestones, plus royalties
- ➤Cash $8.5 million as of September 30, 2026; runway extends into Q1 2027
- ➤VIRAGE2 enrollment expected to complete in Q4 2026; initial data due Q3 2027
- ➤Nine-month net loss $6.7 million versus $21.7 million year-earlier
- ➤VIRAGE analyses published in Nature Medicine showed improved survival with repeated VCN-01 dosing
Expert Statements
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“We are pleased with the clinical progress achieved this quarter”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“The VIRAGE2 trial is a crucial step in the clinical advancement of VCN-01 as we evaluate a dosing regimen that is intended to maximize its potential clinical benefit in different cancer therapy combinations.”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“The publication of detailed analyses of the results from the VIRAGE study in Nature Medicine was a gratifying validation of VCN-01’s novel mode of action and therapeutic potential in metastatic pancreatic ductal adenocarcinoma (PDAC).”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01.”
Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
“In parallel, we continue to evaluate strategic alternatives intended to maximize value for our stockholders.”
– VIRAGE2 enrollment expected to complete in Q4 2026; initial data expected by Q3 2027 –
– Company completes sale of SYN-004 (ribaxamase) and related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. in October, 2026 for $350,000 upfront and up to $91 million in aggregate milestones as well as royalties –
Get started
Create a free account to read the full story.